Justin M. Balko

30.2k total citations · 8 hit papers
152 papers, 11.5k citations indexed

About

Justin M. Balko is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Justin M. Balko has authored 152 papers receiving a total of 11.5k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Oncology, 64 papers in Molecular Biology and 41 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Justin M. Balko's work include Cancer Immunotherapy and Biomarkers (51 papers), Cancer Genomics and Diagnostics (28 papers) and PI3K/AKT/mTOR signaling in cancer (21 papers). Justin M. Balko is often cited by papers focused on Cancer Immunotherapy and Biomarkers (51 papers), Cancer Genomics and Diagnostics (28 papers) and PI3K/AKT/mTOR signaling in cancer (21 papers). Justin M. Balko collaborates with scholars based in United States, Peru and Australia. Justin M. Balko's co-authors include Melinda E. Sanders, Ingrid A. Mayer, Douglas B. Johnson, Luca Gianni, Giampaolo Bianchini, Carlos L. Arteaga, Javid J. Moslehi, Todd W. Miller, Rebecca S. Cook and Caroline A. Nebhan and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

In The Last Decade

Justin M. Balko

143 papers receiving 11.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

2016 2.1k citations Justin M. Balko, Ingrid A. Mayer et al. profile →
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

2018 836 citations Joe‐Elie Salem, Justin M. Balko et al. profile →
Immune-checkpoint inhibitors: long-term implications of toxicity

2022 610 citations Douglas B. Johnson, Javid J. Moslehi et al. profile →
Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy

2019 540 citations Daniel Shae, Douglas B. Johnson et al. profile →
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

2017 479 citations Kyung‐min Lee, Jennifer M. Giltnane et al. profile →
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

2013 475 citations Neil E. Bhola, Justin M. Balko et al. profile →
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

2019 260 citations Douglas B. Johnson, Justin M. Balko et al. Journal for ImmunoTherapy of Cancer profile →
Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response

2022 153 citations Brandie C. Taylor, Justin M. Balko profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Justin M. Balko United States	50	6.1k	5.1k	2.7k	2.5k	2.3k	152	11.5k
Neil A. Bhowmick United States	51	4.3k 0.7×	6.8k 1.3×	1.2k 0.4×	2.6k 1.1×	2.0k 0.9×	144	11.4k
Peter M. Siegel Canada	53	7.0k 1.1×	9.0k 1.7×	1.7k 0.6×	3.6k 1.4×	1.6k 0.7×	148	14.7k
Harriet M. Kluger United States	59	7.7k 1.3×	5.1k 1.0×	3.5k 1.3×	1.3k 0.5×	3.1k 1.4×	319	12.4k
Huamin Wang United States	74	11.5k 1.9×	5.6k 1.1×	2.0k 0.7×	4.5k 1.8×	4.0k 1.8×	256	17.9k
Russell Leek United Kingdom	56	5.1k 0.8×	7.3k 1.4×	2.6k 1.0×	4.5k 1.8×	1.3k 0.6×	109	12.5k
Pascal Finetti France	52	4.9k 0.8×	4.7k 0.9×	1.5k 0.6×	3.5k 1.4×	1.3k 0.6×	175	9.8k
Paula D. Bos United States	17	4.2k 0.7×	5.1k 1.0×	1.5k 0.6×	3.5k 1.4×	1.3k 0.6×	33	9.5k
Andrew V. Biankin Australia	56	7.7k 1.3×	5.3k 1.0×	1.1k 0.4×	3.5k 1.4×	1.8k 0.8×	201	13.4k
Melinda E. Sanders United States	45	6.5k 1.1×	6.0k 1.2×	1.3k 0.5×	4.8k 1.9×	2.5k 1.1×	119	13.3k
Jeffrey R. Infante United States	63	9.0k 1.5×	6.9k 1.3×	2.2k 0.8×	2.5k 1.0×	3.5k 1.6×	343	14.8k

Countries citing papers authored by Justin M. Balko

Since Specialization

Citations

This map shows the geographic impact of Justin M. Balko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Justin M. Balko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Justin M. Balko more than expected).

Fields of papers citing papers by Justin M. Balko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Justin M. Balko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Justin M. Balko. The network helps show where Justin M. Balko may publish in the future.

Co-authorship network of co-authors of Justin M. Balko

This figure shows the co-authorship network connecting the top 25 collaborators of Justin M. Balko. A scholar is included among the top collaborators of Justin M. Balko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Justin M. Balko. Justin M. Balko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

González-Ericsson, Paula I., Susan R. Opalenik, Violeta Sánchez, et al.. (2025). In Situ Detection of Individual Classic MHC-I Gene Products in Cancer. Cancer Immunology Research. 13(4). 602–609. 2 indexed citations

González-Ericsson, Paula I., Nisha Unni, Komal Jhaveri, et al.. (2025). Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2− Metastatic Breast Cancer. Clinical Cancer Research. 31(17). 3652–3661.

Sun, Xiaopeng, Laura C. Kennedy, Paula I. González-Ericsson, et al.. (2024). Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort. Clinical Cancer Research. 30(18). 4077–4081. 6 indexed citations

Goodman, Rachel, Douglas B. Johnson, & Justin M. Balko. (2023). Corticosteroids and Cancer Immunotherapy. Clinical Cancer Research. 29(14). 2580–2587. 73 indexed citations

James, Jamaal L., Brandie C. Taylor, Margaret L. Axelrod, et al.. (2023). Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance. Journal for ImmunoTherapy of Cancer. 11(11). e007736–e007736. 16 indexed citations

Axelrod, Margaret L., Yu Wang, Yaomin Xu, et al.. (2022). Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer. Cancer Research Communications. 2(5). 286–292. 5 indexed citations

González-Ericsson, Paula I., Rosa I. Gallagher, Xiaopeng Sun, et al.. (2021). Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. Clinical Cancer Research. 27(19). 5299–5306. 54 indexed citations

Song, Haocan, Fei Ye, Javid J. Moslehi, et al.. (2020). Demographic Factors Associated with Toxicity in Patients Treated with Anti–Programmed Cell Death-1 Therapy. Cancer Immunology Research. 8(7). 851–855. 42 indexed citations

Ou, Yu‐Chuan, Xiaona Wen, Christopher Andrew Johnson, et al.. (2019). Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies. ACS Nano. 14(1). 651–663. 54 indexed citations

10.

Croessmann, Sarah, Jonathan H. Sheehan, Kyung‐min Lee, et al.. (2017). PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K α Inhibitors. Clinical Cancer Research. 24(6). 1426–1435. 27 indexed citations

11.

Amato, Katherine, Shan Wang, Li Tan, et al.. (2016). EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Research. 76(2). 305–318. 84 indexed citations

12.

Mayer, Ingrid A., Vandana G. Abramson, Luigi Formisano, et al.. (2016). A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer. Clinical Cancer Research. 23(1). 26–34. 241 indexed citations

13.

Williams, Michelle M., Linus Lee, Donna J. Hicks, et al.. (2016). Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade. Molecular Cancer Research. 15(3). 259–268. 41 indexed citations

14.

Bhola, Neil E., Valerie M. Jansen, Sangeeta Bafna, et al.. (2014). Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer. Cancer Research. 75(2). 405–414. 50 indexed citations

15.

Dennison, Jennifer B., Jennifer R. Molina, Shreya Mitra, et al.. (2013). Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer. Clinical Cancer Research. 19(13). 3703–3713. 93 indexed citations

16.

Balko, Justin M., Luis J. Schwarz, Neil E. Bhola, et al.. (2013). Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer. Cancer Research. 73(20). 6346–6358. 122 indexed citations

17.

Miller, Todd W., Justin M. Balko, Zara Ghazoui, et al.. (2011). A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance. Clinical Cancer Research. 17(7). 2024–2034. 85 indexed citations

18.

Fox, Emily M., Todd W. Miller, Justin M. Balko, et al.. (2011). A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer. Cancer Research. 71(21). 6773–6784. 131 indexed citations

19.

Ghosh, Ritwik, Archana Narasanna, Shizhen Emily Wang, et al.. (2011). Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers. Cancer Research. 71(5). 1871–1882. 171 indexed citations

20.

Miller, Todd W., Justin M. Balko, Emily M. Fox, et al.. (2011). ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer. Cancer Discovery. 1(4). 338–351. 241 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact